Anti-VEGF treatment for secondary neovascularization in pseudoxanthoma elasticum - age of onset, treatment frequency and visual outcome

To assess the onset, treatment frequency, and visual outcome of anti-vascular endothelial growth factor (anti-VEGF) treatment due to secondary choroidal neovascularization (CNV) in patients with pseudoxanthoma elasticum (PXE).

Source: American Journal of Ophthalmology - April 11, 2024 Category: Opthalmology Authors: Kristin Raming, Maximilian Pfau, Philipp Herrmann, Frank G. Holz, Kristina Pfau Tags: Original Articles Source Type: research